Abstract
Introduction

Hypereosinophilic syndrome (HES) is a relatively rare hematologic disorder characterized by persistent increased numbers of peripheral eosinophils not caused by other factors, such as hematologic malignancies, allergy, parasitic infection, autoimmune disorders, or concomitant cancerous disease (1-8). HES affects patients with diverse backgrounds, has varied clinical manifestations and different treatment courses. HES has been classified into three subtypes, namely, the myeloproliferative (MP) type, lymphocytic (LC) type and idiopathic type, according to molecular pathophysiology and clinical behavior, and is recently categorized as a chronic myeloproliferative disorder in the latest WHO classification (1)
.
n t i me t e r l e n g t h wi t h t h r o mb u s ( a r r o wh e a d s ) a n d c o l l a t e r a l f o r ma t i o n s ( a r r o ws ) . T h e a r t e r i a l o c c l u s i o n i s i n d i c a t e d b y d o t t e d l i n e s . ( B ) P e r f us i o n d e l a y a n d v e r mi c u l a r -s h a p e d s t r i c t u r e a t t h r e e b r a n c h e s b e l o w t h e p o p l i t e a l a r t e r y we r e i d e nt i f i e d ( a r r o wh e a d s ) .
plus drug therapies including CS and anticoagulant drugs. Following a review of the previously reported 14 cases of HES with peripheral AO and our case, we discuss the risks and histories associated with the development of AO, and suggest treatment for HES with AO (11-23).
Case Report A 19- (Fig. 1A) , perfusion delay and the vermicular-shaped structure at all three branches below the popliteal artery (Fig. 1B) (8, 9) .
Discussion
The present case was diagnosed as HES, according to both the classical Chusid's criteria and the latest WHO classification (1, 3, 7-9). Despite the high serum levels of sIL-2 R and IL-5 at the onset, the patient did not have accompanying T-cell disorder or malignancy. At his first presentation, he was treated with acetaminophen, and he later showed a positive reaction in the drug-lymphocyte stimulation test. It is possible that the abnormal activation of the lymphoid system driven by the acetaminophen treatment might accelerate cytokine production at the initial presentation in this case. However, drug-induced hypereosinophilia was diagnostically excluded, because hypereosinophilia relapsed even after cessation of acetaminophen administration at the onset of AO. The diagnosis of CEL was excluded, because our case did not show the evidence for clonal eosinophil proliferation, such as the FIP1L1-PDGFRα fusion gene, the accumulation of dysplastic mast cells, or high serum levels of vitamin B12 or GM-CSF
During remission after the termination of CS treatment, (11, 12, 23) . Although eosinophils may be directly cytotoxic through the local release of toxic substances including cationic proteins, enzymes, reactive oxygen species, pro-inflammatory cytokines, and arachidonic acid-derived factors (5, 7, 8, 14, 26) 
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